This member of the ovarian tumor domain family of deubiquitinating enzymes abrogates NF-κB signaling by inactivating several proteins required for NF-κB activity, such as TAK1, TRAF6, NF-κB essential modulator, and receptor interacting protein kinase 1 [18–20]. Here, RIPK1 is linked to ovarian neoplasm.